Interpace Biosciences Inc
OTC:IDXG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (8), the stock would be worth $1.23 (36% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 12.4 | $1.92 |
0%
|
| 3-Year Average | 8 | $1.23 |
-36%
|
| 5-Year Average | 3.3 | $0.51 |
-73%
|
| Industry Average | 19.2 | $2.98 |
+55%
|
| Country Average | 19.6 | $3.04 |
+58%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Interpace Biosciences Inc
OTC:IDXG
|
53.2m USD | 12.4 | 2.2 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
100.2B USD | 14.2 | 56 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
68.5B EUR | 10 | 13.5 | |
| US |
|
Cigna Corp
NYSE:CI
|
73.7B USD | 0 | 12.1 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 16.8 | 23.6 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.7B EUR | 13.7 | 17.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.1B USD | 15.7 | 21.2 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.8B USD | 17.2 | 24.7 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 9.9 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.5B USD | -27.4 | -27.6 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.6B USD | 9.7 | 13.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Interpace Biosciences Inc
Glance View
Interpace Biosciences, Inc. operates as a bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. The company is headquartered in Parsippany, New Jersey and currently employs 147 full-time employees. The Company’s clinical services provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer in personalized medicine for improved patient diagnosis and management. Through its pharma services, it develops, commercializes and provides molecular and biomarker-based tests and services. Its pharma services provide pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries and advance personalized medicine. The firm has five commercialized molecular diagnostic tests in the marketplace, which include PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR and RespriDx. Its pipeline product includes BarreGEN.
